SVF Endurance (Cayman) Ltd sold VIR

October 27, 2025 · Form 4 insider transaction

SVF Endurance (Cayman) Ltd sold 66,403 shares of Vir Biotechnology, Inc. at $6.05 per share, a transaction worth $401.6K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.

Direction
Disposed (sell-side)
Shares
66,403
Price
$6.05
Total value
$401.6K
Role
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateOctober 27, 2025
Filing dateOctober 28, 2025
Shares owned after14,598,536
OwnershipIndirect
10b5-1 planYes
AmendedNo

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025.; The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.93 to $6.18. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.; SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.

View the original Form 4 on SEC EDGAR